Harbin Jixianglong Biotech Co., Ltd.: GLP-1 import refusal records

Has FDA refused imports of GLP-1 products from Harbin Jixianglong Biotech Co., Ltd.?

Yes. FDA’s import refusal records list 2 refused shipment lines declared as made by Harbin Jixianglong Biotech Co., Ltd. (China) whose FDA product code names semaglutide and tirzepatide, from Jan 14, 2025 to Aug 6, 2025. 1 of them carry a product code that FDA’s Import Alert 66-80 lists as a GLP-1 API or powder form.

Country
China
City in FDA records
Haerbin
FEI numbers on the lines
3024038751
Refused lines
2
Lines with an Import Alert 66-80 API or powder code
1
Drugs named in the product codes
Semaglutide, Tirzepatide
Refusal dates
Jan 14, 2025 to Aug 6, 2025

The declared manufacturer is the firm named on the import entry. A refusal is FDA’s decision on one shipment line; it is not a finding about the firm’s other products.

Import Alert 66-80’s Green List (published Oct 9, 2026) prints a redaction in place of every firm name, so this index cannot say whether Harbin Jixianglong Biotech Co., Ltd. is on it. Company page with the same legal name: Harbin Jixianglong Biotech Co., Ltd..

Refused shipment lines

FDA refusal chargesShipment ID
Aug 6, 2025China61PCT72 SEMAGLUTIDE (ANTI-DIABETIC)Active Pharm Ingred/Chems for Rx CompoundingDIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use.H77-0229191-2/13/1
Jan 14, 2025China61PCY74 TIRZEPATIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-80DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use.799-5342133-7/11/1

FDA refusal charges on these lines

A line can carry several charges. Text is FDA’s charge statement, verbatim.

DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use.2

FDA NDC listings

FDA’s NDC Directory files, read Nov 15, 2026, list 2 products naming retatrutide and tirzepatide under the labeler name “Harbin Jixianglong Biotech Co., Ltd.”, matched to this import records page by exact name. Marketing categories as FDA gives them: BULK INGREDIENT (2).

84385-103Not givenRetatrutidePOWDERNot given100 g/100gBULK INGREDIENTJan 9, 2025None givenDec 31, 2026Unfinished drugs
84385-104Not givenTirzepatidePOWDERNot given100 g/100gBULK INGREDIENTMay 9, 2025None givenDec 31, 2027Unfinished drugs

FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.

2 lines from FDA files read Nov 15, 2026.